Novartis Home

At Novartis, we are reimagining medicine

Activated T-cells (shown in blue) attack and destroy a cancer cell.

Cell & Gene Therapy at Novartis

Our teams aim to deliver on the promise of cell and gene therapy for patients.

Women in Science: Shannon Campbell

How Shannon Campbell, Senior Vice President & Franchise Head at Novartis Oncology, came into her current role and leadership position.

Nana, a patient from Ghana who shares her sickle cell story in a village near her home.

Sickle Cell Disease

Discover how Novartis is committed to educating about this disease in sharing patient stories from around the world.

#WorldSickleCellDay

Learn More

Transparency

Disclosure of transfers of value to healthcare professionals and support to patient groups in accordance with EFPIA Codes and other local laws and regulations.

Payments to Healthcare Professionals
Patient Organization Funding

Novartis Home

At Novartis, we are reimagining medicine

Cell & Gene Therapy at Novartis

Women in Science: Shannon Campbell

Sickle Cell Disease

FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

Novartis, Amgen and Banner Alzheimer's Institute discontinue clinical program with BACE inhibitor CNP520 for Alzheimer's prevention

Sandoz launches oncology generic gefitinib in 13 EU countries at loss of market exclusivity, expanding access to essential medicine

Novartis highlights cognition data in secondary progressive multiple sclerosis (SPMS)